Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

CD44 Promotes intoxication by the clostridial iota-family toxins.

Wigelsworth DJ, Ruthel G, Schnell L, Herrlich P, Blonder J, Veenstra TD, Carman RJ, Wilkins TD, Van Nhieu GT, Pauillac S, Gibert M, Sauvonnet N, Stiles BG, Popoff MR, Barth H.

PLoS One. 2012;7(12):e51356. doi: 10.1371/journal.pone.0051356. Epub 2012 Dec 7.

2.

Glutamate dehydrogenase is highly conserved among Clostridium difficile ribotypes.

Carman RJ, Wickham KN, Chen L, Lawrence AM, Boone JH, Wilkins TD, Kerkering TM, Lyerly DM.

J Clin Microbiol. 2012 Apr;50(4):1425-6. doi: 10.1128/JCM.05600-11. Epub 2012 Feb 1.

3.

Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency.

Boone JH, Goodykoontz M, Rhodes SJ, Price K, Smith J, Gearhart KN, Carman RJ, Kerkering TM, Wilkins TD, Lyerly DM.

Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1551-9. doi: 10.1007/s10096-011-1477-6. Epub 2011 Dec 14.

PMID:
22167256
4.

Anaerobic Cocci.

Wells CL, Wilkins TD.

In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 19.

5.

Clostridia: Sporeforming Anaerobic Bacilli.

Wells CL, Wilkins TD.

In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 18.

6.

Clostridium difficile binary toxin (CDT) and diarrhea.

Carman RJ, Stevens AL, Lyerly MW, Hiltonsmith MF, Stiles BG, Wilkins TD.

Anaerobe. 2011 Aug;17(4):161-5. doi: 10.1016/j.anaerobe.2011.02.005. Epub 2011 Mar 3.

PMID:
21376825
7.

Clostridium perfringens toxin genotypes in the feces of healthy North Americans.

Carman RJ, Sayeed S, Li J, Genheimer CW, Hiltonsmith MF, Wilkins TD, McClane BA.

Anaerobe. 2008 Apr;14(2):102-8. doi: 10.1016/j.anaerobe.2008.01.003. Epub 2008 Feb 7.

8.

Revised nomenclature of Clostridium difficile toxins and associated genes.

Rupnik M, Dupuy B, Fairweather NF, Gerding DN, Johnson S, Just I, Lyerly DM, Popoff MR, Rood JI, Sonenshein AL, Thelestam M, Wren BW, Wilkins TD, von Eichel-Streiber C.

J Med Microbiol. 2005 Feb;54(Pt 2):113-7.

PMID:
15673503
9.

Clostridium difficile testing: after 20 years, still challenging.

Wilkins TD, Lyerly DM.

J Clin Microbiol. 2003 Feb;41(2):531-4. Review. No abstract available.

10.

A non-toxic lectin for antigen delivery of plant-based mucosal vaccines.

Medina-Bolivar F, Wright R, Funk V, Sentz D, Barroso L, Wilkins TD, Petri W Jr, Cramer CL.

Vaccine. 2003 Feb 14;21(9-10):997-1005.

PMID:
12547614
11.

The mouse model of amebic colitis reveals mouse strain susceptibility to infection and exacerbation of disease by CD4+ T cells.

Houpt ER, Glembocki DJ, Obrig TG, Moskaluk CA, Lockhart LA, Wright RL, Seaner RM, Keepers TR, Wilkins TD, Petri WA Jr.

J Immunol. 2002 Oct 15;169(8):4496-503.

12.

Clostridium difficile toxins A and B can alter epithelial permeability and promote bacterial paracellular migration through HT-29 enterocytes.

Feltis BA, Wiesner SM, Kim AS, Erlandsen SL, Lyerly DL, Wilkins TD, Wells CL.

Shock. 2000 Dec;14(6):629-34.

PMID:
11131913
13.

Fragilysin, the enterotoxin from Bacteroides fragilis, enhances the serum antibody response to antigen co-administered by the intranasal route.

Vines RR, Perdue SS, Moncrief JS, Sentz DR, Barroso LA, Wright RL, Wilkins TD.

Vaccine. 2000 Nov 8;19(6):655-60.

PMID:
11090718
14.

Genetics of Clostridium difficile toxins.

Moncrief JS, Wilkins TD.

Curr Top Microbiol Immunol. 2000;250:35-54. Review. No abstract available.

PMID:
10981356
15.

Clostridium difficile toxins may augment bacterial penetration of intestinal epithelium.

Feltis BA, Kim AS, Kinneberg KM, Lyerly DL, Wilkins TD, Erlandsen SL, Wells CL.

Arch Surg. 1999 Nov;134(11):1235-41; discussion 1241-2.

PMID:
10555639
16.

Varicella vaccination of health-care workers.

Burgess MA, Cossart YE, Wilkins TD, Botham S, Fearns G, Chitour K.

Vaccine. 1999 Feb 26;17(7-8):765-9.

PMID:
10067681
17.

TechLab and alexon Giardia enzyme-linked immunosorbent assay kits detect cyst wall protein 1.

Boone JH, Wilkins TD, Nash TE, Brandon JE, Macias EA, Jerris RC, Lyerly DM.

J Clin Microbiol. 1999 Mar;37(3):611-4.

18.

Comparison of restriction enzyme analysis, arbitrarily primed PCR, and protein profile analysis typing for epidemiologic investigation of an ongoing Clostridium difficile outbreak.

Rafferty ME, Baltch AL, Smith RP, Bopp LH, Rheal C, Tenover FC, Killgore GE, Lyerly DM, Wilkins TD, Schoonmaker DJ, Hannett GE, Shayegani M.

J Clin Microbiol. 1998 Oct;36(10):2957-63.

19.

Molecular characterization of the fragilysin pathogenicity islet of enterotoxigenic Bacteroides fragilis.

Moncrief JS, Duncan AJ, Wright RL, Barroso LA, Wilkins TD.

Infect Immun. 1998 Apr;66(4):1735-9.

20.

Molecular modeling and analysis of fragilysin, the Bacteroides fragilis toxin.

Obiso RJ Jr, Bevan DR, Wilkins TD.

Clin Infect Dis. 1997 Sep;25 Suppl 2:S153-5. No abstract available.

PMID:
9310661
21.

The Bacteroides fragilis toxin fragilysin disrupts the paracellular barrier of epithelial cells.

Obiso RJ Jr, Azghani AO, Wilkins TD.

Infect Immun. 1997 Apr;65(4):1431-9.

22.

Effects of epidermal growth factor and Clostridium difficile toxin B in a model of mucosal injury.

Lawrence JP, Brevetti L, Obiso RJ, Wilkins TD, Kimura K, Soper R.

J Pediatr Surg. 1997 Mar;32(3):430-3.

PMID:
9094010
23.

Positive regulation of Clostridium difficile toxins.

Moncrief JS, Barroso LA, Wilkins TD.

Infect Immun. 1997 Mar;65(3):1105-8.

24.

Cloning and characterization of the gene for the metalloprotease enterotoxin of Bacteroides fragilis.

Kling JJ, Wright RL, Moncrief JS, Wilkins TD.

FEMS Microbiol Lett. 1997 Jan 15;146(2):279-84.

25.

Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A.

Pothoulakis C, Gilbert RJ, Cladaras C, Castagliuolo I, Semenza G, Hitti Y, Montcrief JS, Linevsky J, Kelly CP, Nikulasson S, Desai HP, Wilkins TD, LaMont JT.

J Clin Invest. 1996 Aug 1;98(3):641-9.

26.

Bacteroides fragilis enterotoxin modulates epithelial permeability and bacterial internalization by HT-29 enterocytes.

Wells CL, van de Westerlo EM, Jechorek RP, Feltis BA, Wilkins TD, Erlandsen SL.

Gastroenterology. 1996 May;110(5):1429-37.

PMID:
8613048
27.

Clostridium difficile toxins attack Rho.

Wilkins TD, Lyerly DM.

Trends Microbiol. 1996 Feb;4(2):49-51. Review. No abstract available.

PMID:
8820565
28.

Effects of anti-inflammatory drugs on fever and neutrophilia induced by Clostridium difficile toxin B.

Cardoso RA, Filho AA, Melo MC, Lyerly DM, Wilkins TD, Lima AA, Ribeiro RA, Souza GE.

Mediators Inflamm. 1996;5(3):183-7.

29.

Proteolytic activity of the Bacteroides fragilis enterotoxin causes fluid secretion and intestinal damage in vivo.

Obiso RJ Jr, Lyerly DM, Van Tassell RL, Wilkins TD.

Infect Immun. 1995 Oct;63(10):3820-6.

30.

Dietary modulation of the carcinogenicity of the heterocyclic amines.

Weisburger JH, Rivenson A, Kingston DG, Wilkins TD, Van Tassell RL, Nagao M, Sugimura T, Hara Y.

Princess Takamatsu Symp. 1995;23:240-50.

PMID:
8844815
31.

The enterotoxin of Bacteroides fragilis is a metalloprotease.

Moncrief JS, Obiso R Jr, Barroso LA, Kling JJ, Wright RL, Van Tassell RL, Lyerly DM, Wilkins TD.

Infect Immun. 1995 Jan;63(1):175-81.

32.

Characterization of enterotoxigenic Bacteroides fragilis by a toxin-specific enzyme-linked immunosorbent assay.

Van Tassell RL, Lyerly DM, Wilkins TD.

Clin Diagn Lab Immunol. 1994 Sep;1(5):578-84.

33.

Tox-A Test for Clostridium difficile.

Wilkins TD, Lyerly DM.

J Clin Microbiol. 1994 Sep;32(9):2338. No abstract available.

34.
35.

Mutagenesis of the Clostridium difficile toxin B gene and effect on cytotoxic activity.

Barroso LA, Moncrief JS, Lyerly DM, Wilkins TD.

Microb Pathog. 1994 Apr;16(4):297-303.

PMID:
7968458
36.

Purification and characterization of alpha-toxin produced by Clostridium novyi type A.

Ball DW, Van Tassell RL, Roberts MD, Hahn PE, Lyerly DM, Wilkins TD.

Infect Immun. 1993 Jul;61(7):2912-8.

37.

Production of monoclonal antibodies against Clostridium difficile cytotoxin using immunosorbent binding bioassay procedure.

Depitre C, L'Haridon RM, Lyerly DM, Barroso LA, Wilkins TD, Andremont A, Corthier G.

Toxicon. 1993 Feb;31(2):181-6.

PMID:
8456445
38.

Purification and characterization of Clostridium difficile glutamate dehydrogenase.

Anderson BM, Anderson CD, Van Tassell RL, Lyerly DM, Wilkins TD.

Arch Biochem Biophys. 1993 Jan;300(1):483-8.

PMID:
8424683
39.

The normal intestinal microflora: ecology, variability and stability.

Carman RJ, Van Tassell RL, Wilkins TD.

Vet Hum Toxicol. 1993;35 Suppl 1:11-4. Review.

PMID:
8236752
40.

High-level expression of a heterologous protein in the milk of transgenic swine using the cDNA encoding human protein C.

Velander WH, Johnson JL, Page RL, Russell CG, Subramanian A, Wilkins TD, Gwazdauskas FC, Pittius C, Drohan WN.

Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12003-7.

41.

Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile.

Lyerly DM, Barroso LA, Wilkins TD, Depitre C, Corthier G.

Infect Immun. 1992 Nov;60(11):4633-9.

42.

Production of biologically active human protein C in the milk of transgenic mice.

Velander WH, Page RL, Morcöl T, Russell CG, Canseco R, Young JM, Drohan WN, Gwazdauskas FC, Wilkins TD, Johnson JL.

Ann N Y Acad Sci. 1992 Oct 13;665:391-403. No abstract available.

PMID:
1416618
43.

Cytotoxicity of Clostridium difficile toxin A for human colonic and pancreatic carcinoma cell lines.

Kushnaryov VM, Redlich PN, Sedmak JJ, Lyerly DM, Wilkins TD, Grossberg SE.

Cancer Res. 1992 Sep 15;52(18):5096-9.

44.

Evaluation of systems for collection of porcine zygotes for DNA microinjection and transfer.

Williams BL, Sparks AE, Canseco RS, Knight JW, Johnson JL, Velander WH, Page RL, Drohan WN, Kornegay ET, Pearson RE, Wilkins TD, Gwazdauskas FC.

Theriogenology. 1992 Sep;38(3):501-11.

PMID:
16727153
45.

Isolation of recombinant proteins from milk.

Wilkins TD, Velander W.

J Cell Biochem. 1992 Aug;49(4):333-8. Review.

PMID:
1429861
46.
47.

Purification and characterization of an enterotoxin from Bacteroides fragilis.

Van Tassell RL, Lyerly DM, Wilkins TD.

Infect Immun. 1992 Apr;60(4):1343-50.

48.

Comparison of Clostridium sordellii toxins HT and LT with toxins A and B of C. difficile.

Martinez RD, Wilkins TD.

J Med Microbiol. 1992 Jan;36(1):30-6.

PMID:
1370542
49.

Identification of the latex test-reactive protein of Clostridium difficile as glutamate dehydrogenase.

Lyerly DM, Barroso LA, Wilkins TD.

J Clin Microbiol. 1991 Nov;29(11):2639-42.

50.

In vitro susceptibility of rabbit strains of Clostridium spiroforme to antimicrobial agents.

Carman RJ, Wilkins TD.

Vet Microbiol. 1991 Aug 30;28(4):391-7.

PMID:
1949553

Supplemental Content

Loading ...
Support Center